Enforcement Roundup: Daniel Chapter One, Peanut Corp. Of America

Final chapter for Daniel Chapter One owner; prison sentence for head of salmonella-tainted peanut firm.

James Feijo, owner and operator of [Daniel Chapter One], a dietary supplement marketer that incurred FDA and the Federal Trade Commission enforcement, faces a potential prison sentence after pleading guilty to failing to pay more than $218,000 in employment taxes to the Internal Revenue Service. The Department of Justice on Sept. 15 said Feijo, 68, also pleaded guilty in federal court in Providence, R.I., to marketing and selling products making unapproved claims as cancer mitigation and treatment options. Separately, the Providence firm, which included a home-based church run by Feijo and his wife Trish Feijo, turned to the Supreme Court in 2011 after a lower court upheld FTC's order that the firm made misleading and unsubstantiated claims, including curing cancer, for its shark cartilage and herbal products. The high court declined to hear Feijo’s argument that FTC overstepped its legal authority with its enforcement action, which required the firm to notify customers it did not have sufficient evidence to support the claim Also see "Herbal Firm Denied Supreme Court Hearing Over Cancer Claim" - Pink Sheet, 30 May, 2011.. Feijo’s sentencing is scheduled for Jan. 12, DoJ said.

The former head of Peanut Corporation of America was sentenced to more than 27 years in prison for convictions on charges linked to salmonella-contaminated ingredients and products that caused widespread...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role

 
• By 

By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.

US FDA’s Familiar Drug Pricing To-Do List

 

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric

 

FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.

More from North America

BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says

 

Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.